Cavin Sabrina, Gkasti Aspasia, Faget Julien, Hao Yameng, Letovanec Igor, Reichenbach Maxime, Gonzalez Michel, Krueger Thorsten, Dyson Paul J, Meylan Etienne, Perentes Jean Y
Division of Thoracic Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Eur J Cardiothorac Surg. 2020 Oct 1;58(4):783-791. doi: 10.1093/ejcts/ezaa145.
Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Approaches to enhance patient immunity against MPM have been tested but shown variable results. Previously, we have demonstrated interesting vascular modulating properties of low-dose photodynamic therapy (L-PDT) on MPM. Here, we hypothesized that L-PDT vascular modulation could favour immune cell extravasation in MPM and improve tumour control in combination with immune checkpoint inhibitors.
First, we assessed the impact of L-PDT on vascular endothelial E-selectin expression, a key molecule for immune cell extravasation, in vitro and in a syngeneic murine model of MPM. Second, we characterized the tumour immune cell infiltrate by 15-colour flow cytometry analysis 2 and 7 days after L-PDT treatment of the murine MPM model. Third, we determined how L-PDT combined with immune checkpoint inhibitor anti-CTLA4 affected tumour growth in a murine MPM model.
L-PDT significantly enhanced E-selectin expression by endothelial cells in vitro and in vivo. This correlated with increased CD8+ T cells and activated antigen-presenting cells (CD11b+ dendritic cells and macrophages) infiltration in MPM. Also, compared to anti-CTLA4 that only affects tumour growth, the combination of L-PDT with anti-CTLA4 caused complete MPM regression in 37.5% of animals.
L-PDT enhances E-selectin expression in the MPM endothelium, which favours immune infiltration of tumours. The combination of L-PDT with immune checkpoint inhibitor anti-CTLA4 allows best tumour control and regression.
恶性胸膜间皮瘤(MPM)是一种致命疾病,治疗选择有限。增强患者对MPM免疫的方法已得到测试,但结果各异。此前,我们已证明低剂量光动力疗法(L-PDT)对MPM具有有趣的血管调节特性。在此,我们假设L-PDT的血管调节可促进免疫细胞在MPM中的外渗,并与免疫检查点抑制剂联合使用时改善肿瘤控制。
首先,我们在体外和MPM同基因小鼠模型中评估L-PDT对血管内皮E-选择素表达的影响,E-选择素是免疫细胞外渗的关键分子。其次,我们在对小鼠MPM模型进行L-PDT治疗后2天和7天,通过15色流式细胞术分析对肿瘤免疫细胞浸润进行表征。第三,我们确定L-PDT与免疫检查点抑制剂抗CTLA4联合使用如何影响小鼠MPM模型中的肿瘤生长。
L-PDT在体外和体内均显著增强内皮细胞的E-选择素表达。这与MPM中CD8+T细胞增加以及活化的抗原呈递细胞(CD11b+树突状细胞和巨噬细胞)浸润相关。此外,与仅影响肿瘤生长的抗CTLA4相比,L-PDT与抗CTLA4联合使用使37.5%的动物MPM完全消退。
L-PDT增强MPM内皮中的E-选择素表达,有利于肿瘤的免疫浸润。L-PDT与免疫检查点抑制剂抗CTLA4联合使用可实现最佳的肿瘤控制和消退。